Secukinumab and Bimekizumab for Hidradenitis Suppurativa

Patients with HS are getting a long-awaited influx of targeted therapies. Jennifer L. Hsiao, MD, discusses their immediate impact.

Related Keywords

Jenniferl Hsiao , ,Society For Dermatology Physician Assistants ,Keck School Of Medicine ,Drug Administration ,Dermatology Physician Assistants ,Keck School ,Hidradenitis Suppurativa Clinical Response ,